STOCK TITAN

ENDRA Life Sciences Announces Participation in A.G.P.'s Virtual MedTech Summer Conference on July 29, 2021

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

ENDRA Life Sciences Inc. (NASDAQ:NDRA) will participate in A.G.P.'s Virtual MedTech Summer Conference on July 29, 2021. This event includes 1-on-1 virtual investor meetings, allowing investors to connect with the management team. ENDRA is a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a technology that visualizes tissue at a fraction of MRI costs. TAEUS® targets chronic liver conditions like Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), affecting over one billion people globally.

Positive
  • Participation in A.G.P.'s Virtual MedTech Summer Conference may enhance investor relations.
  • TAEUS® technology offers a cost-effective solution for visualizing tissue, potentially increasing market adoption.
Negative
  • None.

ANN ARBOR, MI / ACCESSWIRE / July 20, 2021 / ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that management will participate in A.G.P.'s Virtual MedTech Summer Conference on Thursday, July 29, 2021.

The event will consist of 1-on-1 virtual investor meetings. Investors participating in the virtual conference who are interested in meeting with members of ENDRA's management team should contact their A.G.P. representative.

About ENDRA Life Sciences Inc.

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with 400,000 cart-based ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.

Company Contact:
Irina Pestrikova
Senior Director, Finance
investors@endrainc.com
www.endrainc.com

Investor Relations Contact:
Yvonne Briggs
LHA Investor Relations
(310) 691-7100
YBriggs@lhai.com

SOURCE: ENDRA Life Sciences Inc.



View source version on accesswire.com:
https://www.accesswire.com/656074/ENDRA-Life-Sciences-Announces-Participation-in-AGPsVirtual-MedTech-Summer-Conference-on-July-29-2021

FAQ

What is ENDRA Life Sciences participating in on July 29, 2021?

ENDRA Life Sciences is participating in A.G.P.'s Virtual MedTech Summer Conference.

What technology does ENDRA Life Sciences develop?

ENDRA Life Sciences develops Thermo Acoustic Enhanced UltraSound (TAEUS®) technology.

What are the clinical applications of TAEUS®?

TAEUS® is primarily focused on measuring fat in the liver to assess Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH).

How does TAEUS® compare to MRI in terms of cost?

TAEUS® visualizes tissue at approximately 1/50th the cost of MRI.

ENDRA Life Sciences Inc.

NASDAQ:NDRA

NDRA Rankings

NDRA Latest News

NDRA Stock Data

2.88M
535.45k
0.28%
0.49%
4.64%
Diagnostics & Research
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
ANN ARBOR